Entrada Therapeutics (TRDA) FCF Margin (2023 - 2026)
Entrada Therapeutics (TRDA) posted quarterly FCF Margin of 4765.14% for Q1 2026, down 457731.0% year-over-year from N/an in Q1 2025, and down 91.5% quarter-over-quarter from 2488.38% in Q4 2025.
Powered by 
Analysis
Entrada Therapeutics (TRDA) FCF Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' FCF Margin history runs 4 years deep, the most recent figure standing at 4765.14% for Q1 2026.
- In Q1 2026, FCF Margin fell 457731.0% year-over-year to 4765.14%; the TTM figure through Mar 2026 stood at 2293.34% (down 225984.0% YoY), while the FY2025 annual figure was 505.53%, down 48432.0% from the prior year.
- FCF Margin for Q1 2026 stood at 4765.14%, down from 2488.38% in the prior quarter.
- The five-year high for FCF Margin was 771.05% in Q1 2023, with the low at 4765.14% in Q1 2026.
- The 4-year median for FCF Margin is 103.92% (2024), against an average of 796.7%.
- The sharpest annual moves came in 2024 and 2026: FCF Margin jumped 19070 bps in 2024, then plunged 457731 bps in 2026.
- Entrada Therapeutics' FCF Margin stood at 11.92% in 2023, then tumbled by 726 bps to 98.42% in 2024, then sank by 2428 bps to 2488.38% in 2025, then sank by 91 bps to 4765.14% in 2026.
- Business Quant data shows TRDA's FCF Margin at 4765.14% in Q1 2026, 2488.38% in Q4 2025, and 1751.98% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Entrada Therapeutics | 297.03 Mn | 297.03 Mn | - | -3,616.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,616.26% |
| Mar 31, 2026 | -4,770.17% |
| Dec 31, 2025 | -2,463.13% |
| Sep 30, 2025 | -1,743.62% |
| Jun 30, 2025 | -1,526.36% |
| Mar 31, 2025 | -192.87% |
| Dec 31, 2024 | -86.21% |
| Sep 30, 2024 | -147.33% |
| Jun 30, 2024 | 45.11% |
| Mar 31, 2024 | -44.58% |
| Dec 31, 2023 | -9.13% |
| Sep 30, 2023 | -61.59% |
| Jun 30, 2023 | -196.86% |
| Mar 31, 2023 | 771.05% |